Tin tức & Cập nhật

Sofosbuvir–velpatasvir treatment of HCV with decompensated cirrhosis works in real world

02 Feb 2021 bởi

The combination of sofosbuvir plus velpatasvir does as well in the real world as in a Japanese phase III trial in hepatitis C virus (HCV) patients with decompensated cirrhosis, although there have been incidences of treatment discontinuation and liver disease-related death, as reported by a team of researchers.

Sofosbuvir–velpatasvir treatment of HCV with decompensated cirrhosis works in real world

02 Feb 2021

Final ClarIDHy findings boost clinical benefit of ivosidenib for rare aggressive biliary cancer

02 Feb 2021 bởi

In the final analysis of the phase III ClarIDHy trial, ivosidenib was well-tolerated and had a favourable overall survival (OS) benefit despite a high crossover rate from placebo among individuals with previously treated advanced cholangiocarcinoma and an isocitrate dehydrogenase 1 mutation (mIDH1 CCA).

Final ClarIDHy findings boost clinical benefit of ivosidenib for rare aggressive biliary cancer

02 Feb 2021

RAINBOW-Asia underlines benefit of ramucirumab-paclitaxel for stomach cancer

01 Feb 2021 bởi

The addition of the human immunoglobulin G1 monoclonal antibody ramucirumab to paclitaxel led to a significant progression-free survival (PFS) benefit in a subgroup of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have failed standard first-line chemotherapy with platinum and fluoropyrimidine (with or without anthracycline), according to the findings of the RAINBOW-Asia study, a bridging study of the RAINBOW trial, presented at ASCO GI 2021.

RAINBOW-Asia underlines benefit of ramucirumab-paclitaxel for stomach cancer

01 Feb 2021

Obeticholic acid safe, effective in select patients with primary biliary cholangitis

30 Jan 2021

Obeticholic acid is beneficial to primary biliary cholangitis patients with suboptimal response to ursodeoxycholic acid, significantly improving prognostic score with good tolerability, according to the results of an open-label study.

Obeticholic acid safe, effective in select patients with primary biliary cholangitis

30 Jan 2021

Can marijuana use improve control of IBS symptoms?

30 Jan 2021

Among patients with irritable bowel syndrome (IBS), use of marijuana has no effect on 30-day hospital readmission for IBS-specific causes but may lower that for all causes, a study has found.

Can marijuana use improve control of IBS symptoms?

30 Jan 2021

Treat IBD first in kids with COVID-19

29 Jan 2021 bởi

Clinicians should first treat inflammatory bowel disease (IBD) in children with COVID-19, says an expert.

Treat IBD first in kids with COVID-19

29 Jan 2021

Water jelly aids in both rehabilitation, prevention of aspiration pneumonia

29 Jan 2021

In elderly patients with moderate-to-severe dysphagia, ingestion of water jelly effectively rehabilitates and manages aspiration pneumonia, a study reports.

Water jelly aids in both rehabilitation, prevention of aspiration pneumonia

29 Jan 2021

Ozanimod benefits UC by lowering inflammation markers in the gut

28 Jan 2021 bởi

One way the S1P* receptor modulator ozanimod reduces disease activity in patients with ulcerative colitis (UC) is by driving down biomarkers of intestinal inflammation such as faecal calprotectin (FCP) and faecal lactoferrin (FLF), according to the TOUCHSTONE study presented at the 2021 Crohn’s and Colitis Congress.

Ozanimod benefits UC by lowering inflammation markers in the gut

28 Jan 2021

Anti-TNF exposure may increase BMI in children with Crohn’s disease

28 Jan 2021 bởi

Exposure to anti-TNF therapy appears to be associated with an increased body mass index (BMI) z-score in paediatric patients with Crohn’s disease, according to a study presented at Crohn’s & Colitis Congress 2021.

Anti-TNF exposure may increase BMI in children with Crohn’s disease

28 Jan 2021

Gut dysbiosis linked to COVID-19 severity and persistent symptoms after viral clearance

27 Jan 2021 bởi

Altered gut microbiota composition in patients with coronavirus disease 2019 (COVID-19) compared with controls is linked to COVID-19 severity and may contribute to persistent symptoms after viral clearance, according to a study by the Chinese University of Hong Kong (CUHK).

Gut dysbiosis linked to COVID-19 severity and persistent symptoms after viral clearance

27 Jan 2021

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Sofosbuvir–velpatasvir treatment of HCV with decompensated cirrhosis works in real world

Sofosbuvir–velpatasvir treatment of HCV with decompensated cirrhosis works in real world

Final ClarIDHy findings boost clinical benefit of ivosidenib for rare aggressive biliary cancer

Final ClarIDHy findings boost clinical benefit of ivosidenib for rare aggressive biliary cancer

RAINBOW-Asia underlines benefit of ramucirumab-paclitaxel for stomach cancer

RAINBOW-Asia underlines benefit of ramucirumab-paclitaxel for stomach cancer

Obeticholic acid safe, effective in select patients with primary biliary cholangitis

Obeticholic acid safe, effective in select patients with primary biliary cholangitis

Can marijuana use improve control of IBS symptoms?

Can marijuana use improve control of IBS symptoms?

Treat IBD first in kids with COVID-19

Treat IBD first in kids with COVID-19

Water jelly aids in both rehabilitation, prevention of aspiration pneumonia

Water jelly aids in both rehabilitation, prevention of aspiration pneumonia

Ozanimod benefits UC by lowering inflammation markers in the gut

Ozanimod benefits UC by lowering inflammation markers in the gut

Anti-TNF exposure may increase BMI in children with Crohn’s disease

Anti-TNF exposure may increase BMI in children with Crohn’s disease

Gut dysbiosis linked to COVID-19 severity and persistent symptoms after viral clearance

Gut dysbiosis linked to COVID-19 severity and persistent symptoms after viral clearance